Sign In
Buy CMPS
$12.69
-0.640 (-4.80%)
At Close: Jun 03, 2026
Meta to roll out AI-powered ad creation by late 2025, says WSJ
10:54am, Monday, 02'nd Jun 2025
Meta Platforms Inc (NASDAQ:META, ETR:FB2A, SWX:FB) is planning to let brands fully create and target ads using its artificial intelligence tools by the end of 2025, according to a report in the Wall S
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 14'th May 2025
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
06:30am, Wednesday, 14'th May 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript
11:14am, Thursday, 08'th May 2025
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical O
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
06:30am, Thursday, 08'th May 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced toda
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
06:30am, Monday, 28'th Apr 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Why Compass Pathways Stock Was a Double-Digit Winner This Week
06:13pm, Friday, 25'th Apr 2025
The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc
This Is a Test From GlobeNewswire
05:01pm, Friday, 28'th Mar 2025
This is a test from GlobeNewswire. Readers are advised to disregard.
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
06:30am, Wednesday, 26'th Mar 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
06:30am, Tuesday, 18'th Mar 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc
Compass Pathways to Participate in Stifel Virtual CNS Forum
06:30am, Tuesday, 11'th Mar 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways: Betting On The Future Of Psilocybin Therapy
05:08pm, Friday, 28'th Feb 2025
Compass Pathways is positioned to leverage regulatory tailwinds and compelling clinical data, despite broader skepticism and high cash burn in the psychedelic biotech sector. The company has a financi
COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript
10:41am, Thursday, 27'th Feb 2025
COMPASS Pathways plc (NASDAQ:CMPS ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief
